Literature DB >> 2879793

Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans.

K N Mendis, Y D Munesinghe, Y N de Silva, I Keragalla, R Carter.   

Abstract

Immunity to malarial infections in human populations is known to affect the development of the asexual blood stages of the parasites in the human host and to be capable of conferring significant protection against morbidity and mortality due to the disease. In this study we show that during acute infection with Plasmodium vivax malaria, one of the two main malarial pathogens of humans, most individuals also develop immunity that suppresses the infectivity of the sexual stages of the parasite to mosquitoes. The immunity is antibody mediated and is directed against the parasites in the mosquito midgut shortly after ingestion of blood by a mosquito. This immunity could be expected to have significant effects on the natural transmission of P. vivax malaria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2879793      PMCID: PMC260336          DOI: 10.1128/iai.55.2.369-372.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Gamma-globulin and acquired immunity to human malaria.

Authors:  S COHEN; I A McGREGOR; S CARRINGTON
Journal:  Nature       Date:  1961-11-25       Impact factor: 49.962

2.  Successful immunization against the sexual stages of Plasmodium gallinaceum.

Authors:  R W Gwadz
Journal:  Science       Date:  1976-09-17       Impact factor: 47.728

3.  Immunosuppression in children with malaria.

Authors:  B M Greenwood; A M Bradley-Moore; A D Bryceson; A Palit
Journal:  Lancet       Date:  1972-01-22       Impact factor: 79.321

4.  Immunisation against gametes and asexual erythrocytic stages of a rodent malaria parasite.

Authors:  K N Mendis; G A Targett
Journal:  Nature       Date:  1979-02-01       Impact factor: 49.962

5.  Plasmodium gallinaceum: Transmission-blocking immunity in chickens. II. The effect of antigamete antibodies in vitro and in vivo and their elaboration during infection.

Authors:  R Carter; R W Gwadz; I Green
Journal:  Exp Parasitol       Date:  1979-04       Impact factor: 2.011

6.  Immunization to produce a transmission-blocking immunity in Plasmodium yoelii malaria infections.

Authors:  K N Mendis; G A Targett
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

7.  Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes.

Authors:  D C Kaushal; R Carter; J Rener; C A Grotendorst; L H Miller; R J Howard
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria.

Authors:  E H Nardin; R S Nussenzweig; I A McGregor; J H Bryan
Journal:  Science       Date:  1979-11-02       Impact factor: 47.728

9.  Malaria immunization in Rhesus monkeys. A vaccine effective against both the sexual and asexual stages of Plasmodium knowlesi.

Authors:  R W Gwadz; I Green
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum.

Authors:  J Rener; P M Graves; R Carter; J L Williams; T R Burkot
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  39 in total

1.  Western blot diagnosis of vivax malaria with multiple stage-specific antigens of the parasite.

Authors:  E S Son; T S Kim; H W Nam
Journal:  Korean J Parasitol       Date:  2001-06       Impact factor: 1.341

Review 2.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

3.  A mathematical model for Plasmodium vivax malaria transmission: estimation of the impact of transmission-blocking immunity in an endemic area.

Authors:  A P De Zoysa; C Mendis; A C Gamage-Mendis; S Weerasinghe; P R Herath; K N Mendis
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

4.  Analysis of immunity induced by the affinity-purified 21-kilodalton zygote-ookinete surface antigen of Plasmodium berghei.

Authors:  N Tirawanchai; L A Winger; J Nicholas; R E Sinden
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 5.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 6.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

7.  Malaria-induced changes in host odors enhance mosquito attraction.

Authors:  Consuelo M De Moraes; Nina M Stanczyk; Heike S Betz; Hannier Pulido; Derek G Sim; Andrew F Read; Mark C Mescher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 8.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

9.  Evaluation of the effect of host immune status on short-term Yersinia pestis infection in fleas with implications for the enzootic host model for maintenance of Y. pestis during interepizootic periods.

Authors:  Christine B Graham; Michael E Woods; Sara M Vetter; Jeannine M Petersen; John A Montenieri; Jennifer L Holmes; Sarah E Maes; Scott W Bearden; Kenneth L Gage; Rebecca J Eisen
Journal:  J Med Entomol       Date:  2014-09       Impact factor: 2.278

10.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.